38 completed, 22 recruiting, 17 unknown, 10 terminated. 34 Phase 2, 17 Phase 1, 15 Phase 3, 9 Not applicable, 3 Early Phase 1.
Follow Primary Sclerosing Cholangitis: new trials by email Literature Review of Primary Sclerosing Cholangitis trials Research Report on Primary Sclerosing Cholangitis
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Nemolizumab for the Treatment of Moderate to Severe Chronic Hepatic Pruritus Nemolizumab-ilto - Chronic Hepatic Pruritus, Cholestatic Liver Disease | Phase 2 | Not yet recruiting | Mayo Clinic | 15 | 2026-11-01 | 2026-09-28 |
| LEOPARD Prospective Validation Cohort 1 Standardized assessments, guided tumor biopsy and biobanking, Standardized assessments and biobanking - Decompensated Liver Cirrhosis, Primary Biliary Cholangitis | Recruiting | Assistance Publique - Hôpitaux de Paris | 630 | 2026-07-07 | 2026-07-29 | |
| A Study to Assess How Well and Safely Elafibranor Works in Adult Participants With Primary Sclerosing Cholangitis Elafibranor, Placebo - Primary Sclerosing Cholangitis | Phase 3 | Recruiting | Ipsen | 350 | 2026-05-14 | 2026-10-23 |
| A Study of TAK-781 in Healthy Volunteers and in Participants With Non-Cirrhotic Primary Sclerosing Cholangitis (PSC) TAK-781, Placebo - Healthy Volunteers, Primary Sclerosing Cholangitis | Phase 1 | Recruiting | Takeda | 134 | 2026-01-07 | 2026-03-05 |
| A Study Evaluating the Safety, Tolerability, and Efficacy of Aramchol Meglumine in Primary Sclerosing Cholangitis Aramchol meglumine - Primary Sclerosing Cholangitis | Phase 2 | Withdrawn | Galmed Pharmaceuticals Ltd | 2025-06-01 | 2025-06-12 | |
| Pharmacologic Approaches to Preventing Primary Sclerosing Cholangitis Recurrence After Liver Transplantation Fenofibrate (drug), Blood draw for the laboratory assessment, MRI using a hepatobiliary phase contrast agent (Gd-EOB-DPTA) - Primary Sclerosing Cholangitis, Liver Transplant, Complications | Phase 2 | Recruiting | Mayo Clinic | 80 | 2025-04-15 | 2026-07-17 |
| Study with Norucholic Acid Tablets in Patients with Primary Sclerosing Cholangitis (PSC) norucholic acid - Primary Sclerosing Cholangitis | Phase 3 | Not yet recruiting | Dr. Falk Pharma GmbH | 120 | 2025-03-01 | 2025-03-20 |
| LEOPARD Training and Validation Data Collection Study Decompensated Liver Cirrhosis, Primary Biliary Cholangitis | Recruiting | Assistance Publique - Hôpitaux de Paris | 4500 | 2025-02-04 | 2026-07-29 | |
| A Multi-center Evaluation of Aldafermin in a Randomized, Double-blind, Placebo-controlled Study in Subjects With Primary Sclerosing Cholangitis. aldafermin, Placebo - Primary Sclerosing Cholangitis | Phase 2 / Phase 3 | Withdrawn | NGM Biopharmaceuticals, Inc | 2024-10-21 | 2025-05-07 | |
| A Study of SIPLIZUMAB in AILD and LT Patients Siplizumab - Autoimmune Liver Disease, Liver Transplant Disorder | Phase 1 | Recruiting | Elizabeth C. Verna | 8 | 2024-09-11 | 2025-11-24 |
| TruGraf Liver Gene Expression Serial Test TruGraf® - Autoimmune Liver Disease, Autoimmune Hepatitis | Terminated | Washington University School of Medicine | 13 | 2024-08-01 | 2026-08-07 | |
| Liver-gut Axis Study Through Identification of Liver Disease-specific Microbiome Autoimmune Hepatitis, Primary Sclerosing Cholangitis | Recruiting | Chungnam National University Hospital | 3000 | 2024-07-08 | 2026-03-20 | |
| The Effects of Bromelain Supplement in Patients With Ulcerative Colitis Bromlein, Placebo - Ulcerative Colitis, Primary Sclerosing Cholangitis | Phase 2 / Phase 3 | Completed | National Nutrition and Food Technology Institute | 52 | 2024-04-20 | 2026-10-27 |
| FAecal Microbiota Transplantation in primaRy sclerosinG chOlangitis Faecal Microbiota Transplant, FMT Placebo - Primary Sclerosing Cholangitis, Inflammatory Bowel Diseases | Phase 2 | Recruiting | University of Birmingham | 58 | 2024-03-27 | 2026-09-24 |
| Evaluation of an Oral Microbiota-based Therapeutic as a Treatment Option for PSC oral vancomycin and oral amoxicillin - Primary Sclerosing Cholangitis | Early Phase 1 | Recruiting | University of Minnesota | 28 | 2024-03-01 | 2026-05-20 |
| Detoxification of the Liver In PSC (Dolphin) BRS201, Placebo - Primary Sclerosing Cholangitis | Phase 2 | Recruiting | Brigham and Women's Hospital | 28 | 2023-12-12 | 2026-07-21 |
| CS0159 in Chinese Patients With PSC (Primary Sclerosing Cholangitis) CS0159 - Primary Sclerosing Cholangitis | Phase 2 | Active not recruiting | Cascade Pharmaceuticals, Inc | 50 | 2023-08-07 | 2026-03-13 |
| Vancomycin in Primary Sclerosing Cholangitis in Italy Oral Vancomycin, Placebo - Primary Sclerosing Cholangitis, Liver and Intrahepatic Bile Duct Disorder | Phase 2 | Recruiting | University of Milano Bicocca | 84 | 2023-06-15 | 2025-07-25 |
| Statin Therapy in Primary Sclerosing Cholangitis (PSC): a Multi-omics Study Rosuvastatin - Primary Sclerosing Cholangitis, Inflammatory Bowel Diseases | Early Phase 1 | Recruiting | Stanford University | 15 | 2023-05-31 | 2026-02-27 |
| Oral Hymecromone to Treat Adolescents and Adults With Primary Sclerosing Cholangitis. Hymecromone - Primary Sclerosing Cholangitis | Phase 2 | Recruiting | Aparna Goel | 24 | 2023-05-10 | 2025-06-13 |
Showing 20 of 103. Sign in to see all of them.
Cholangitis, Sclerosing (103) · Inflammatory Bowel Diseases (11) · Liver Cirrhosis, Biliary (11) · Hepatitis, Autoimmune (10) · Cholestasis (7) · Cholangiocarcinoma (5) · Liver Diseases (5) · Cholangitis (4) · Bile Duct Diseases (3) · Biliary Atresia (3) · Biliary Tract Diseases (3) · Colitis, Ulcerative (3) · Digestive System Diseases (3) · Fibrosis (3) · Pruritus (3)
Bile Duct Diseases (100) · Biliary Tract Diseases (100) · Digestive System Diseases (100) · Cholangitis (99) · Pathological Conditions, Signs and Symptoms (17) · Liver Diseases (16) · Gastroenteritis (15) · Gastrointestinal Diseases (15) · Pathologic Processes (15) · Intestinal Diseases (14) · Fibrosis (12) · Cholestasis, Intrahepatic (11) · Liver Cirrhosis (11) · Autoimmune Diseases (10) · Hepatitis (10)
Vancomycin (11) · Ursodeoxycholic Acid (3) · cilofexor (3) · 2-(2,6-dimethyl-4-(3-(4-(methylthio)phenyl)-3-oxo-1-propenyl)phenoxyl)-2-methylpropanoic acid (2) · Bezafibrate (2) · Fenofibrate (2) · Metronidazole (2) · Multiparametric Magnetic Resonance Imaging (2) · aldafermin (2) · (2-methyl-4-(5-methyl-2-(4-trifluoromethyl-phenyl)-2H-(1,2,3)triazol-4-ylmethylsulfanyl)phenoxy)acetic acid (1) · 24-norursodeoxycholic acid (1) · Amoxicillin (1) · Blood Specimen Collection (1) · Capecitabine (1) · Colonoscopy (1)
Mayo Clinic (10) · Gilead Sciences (5) · Stanford University (4) · Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) (3) · Assistance Publique - Hôpitaux de Paris (3) · Brigham and Women's Hospital (3) · Children's Hospital Medical Center, Cincinnati (3) · Dr. Falk Pharma GmbH (3) · Perspectum (3) · Beth Israel Deaconess Medical Center (2) · Elizabeth Carey (2) · HighTide Therapeutics (Hong Kong) Limited (2) · Ipsen (2) · Karolinska University Hospital (2) · NGM Biopharmaceuticals, Inc (2)
United States (55) · United Kingdom (14) · Germany (11) · Canada (10) · France (10) · Italy (10) · Netherlands (10) · Belgium (8) · Spain (8) · Austria (7) · Sweden (6) · Australia (5) · China (5) · Israel (5) · Denmark (3)
Alexander Miethke, MD (2) · Elizabeth Carey, MD (2) · Michael Trauner, MD (2) · Alastair Smith, MD (1) · Amy E Taylor, MD (1) · Andrew Muir, MD (1) · Annika Bergquist, MD PhD (1) · Annika Bergquist, PhD (1) · Aparna Goel, MD (1) · Arun Sanyal, MD (1) · Azita Hekmatdoost, MD, PhD (1) · Benjamin Shneider, M.D. (1) · Byron P Vaughn, MD (1)
PMID 23054338, PMID 32633158, PMID 41804276, PMID 19585548, PMID 23384404, PMID 24206748, PMID 26048252, PMID 28249726, PMID 28529147, PMID 28535810, PMID 28674140, PMID 29803836, PMID 30661255, PMID 31611594, PMID 33031833, PMID 33681680, PMID 33798541, PMID 33898959, PMID 35080454, PMID 36520162, PMID 37055910, PMID 38630086, PMID 38976363, PMID 38977324, PMID 39601354, PMID 39673746, PMID 39762111, PMID 40350321, PMID 41016442, PMID 41173015, PMID 41513411, PMID 42489629
2014 (2), 2019 (2), 2015 (1), 2016 (1), 2018 (1), 2023 (1), R01DK056924 (1), R03DK071851 (1), RC2DK118619 (1), U24DK062456 (1)